Track Sudeep Pharma Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: -5.98 %
Low
788.4
High
894.5
1 Month returns: 8.41 %
Low
721.8
High
894.5
1 Year returns: –
3 Year CAGR: –
5 Year CAGR: –
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Sudeep Pharma Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Sudeep Pharma Ltd. Shareholding Pattern
Quarterly breakdown of Sudeep Pharma Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Sudeep Pharma Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Sudeep Pharma Ltd.?
The current share price of Sudeep Pharma Ltd. is ₹ 803.95 as of 9 Jul 2026.
What is the market capitalisation of Sudeep Pharma Ltd.?
The market capitalisation of Sudeep Pharma Ltd. stands at ₹ 9,039.31 Cr.
What is the PE ratio of Sudeep Pharma Ltd.?
The Price-to-Earnings (PE) ratio of Sudeep Pharma Ltd. is 52.28 as of the latest trailing twelve months data.
What is the ROE and ROCE of Sudeep Pharma Ltd.?
Sudeep Pharma Ltd. has a Return on Equity (ROE) of 25.12% and a Return on Capital Employed (ROCE) of 24.67% as per the latest financial reports.
What is the 52-week high and low of Sudeep Pharma Ltd.?
The 52-week high of Sudeep Pharma Ltd. is - and the 52-week low is -.
What is the dividend yield of Sudeep Pharma Ltd.?
The dividend yield of Sudeep Pharma Ltd. is 0.00% based on the current market price.
What is the FII and DII holding in Sudeep Pharma Ltd.?
Foreign Institutional Investors (FII) hold 1.55%, Domestic Institutional Investors (DII) hold 7.35% and retail/public investors hold 3.98% of Sudeep Pharma Ltd. shares.
What sector does Sudeep Pharma Ltd. belong to?
Sudeep Pharma Ltd. operates in the Healthcare sector.
What is the beta of Sudeep Pharma Ltd.?
The beta of Sudeep Pharma Ltd. is -, indicating its price volatility relative to the broader market.
What is the RSI of Sudeep Pharma Ltd.?
The 14-day Relative Strength Index (RSI) of Sudeep Pharma Ltd. is 50.31, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Company Profile
Overview of Sudeep Pharma Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Sudeep Pharma Private Limited is an India-based manufacturing pharmaceutical and nutraceutical products company. The Company is engaged in business of manufacturing and selling pharmaceutical and food, nutrition and specialty ingredients and intermediaries, used by pharmaceutical, food and nutrition industries globally. The Company a wide range of products, including mineral salts such as calcium salts, zinc salts, iron salts, potassium salts, magnesium salts, sodium salts, simethicone salts and copper salts. It offers products to a wide range of markets, which includes pharmaceuticals, dietary health, infant nutrition, beverage, dairy products, bakery products, confectionery, and staple food markets. Its subsidiaries include Sudeep Nutrition Private Limited, Sudeep Pharma USA Inc., Sudeep Pharma B.V., and Sudeep Advanced Materials Private Limited.
Sudeep Pharma Private Limited is an India-based manufacturing pharmaceutical and nutraceutical products company. The Company is engaged in business of manufacturing and selling pharmaceutical and food, nutrition and specialty ingredients and intermediaries, used by pharmaceutical, food and nutrition...
Fundamental analysis overview of Sudeep Pharma Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
High ROE
The company reported strong ROE of 25.12% for 12-month ended 31 Mar 2026
What is ROE (FY)?
High operating margin
The company reported strong operating margin of 32.24% for 12-month ended 31 Mar 2026
What is Operating profit margin?
Strong revenue growth and above median growth of industry
The company delivered strong revenue growth of 29.12% for 12-month ended 31 Mar 2026 and the growth was 17.88 percentage points higher than median growth of industry
What is Sales growth (1Y)?
Median: 11.24
Value 29.12
-82.35114662
Strong EPS growth and above median growth of industry
The company delivered strong EPS growth of 26.2% for 12-month ended 31 Mar 2026 and the growth was 18.08 percentage points higher than median growth of industry
What is EPS growth (1Y)?
Low Debt to Equity
The company has low Debt to Equity of 0.17 as on 31 Mar 2026
What is Debt to Equity?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 52.28 indicates that the stock is expensive on a standalone basis and is at a 72.14% premium to industry median P/E
What is P/E Ratio?
Median: 30.37
Value 52.28
-215.443255.34
Analysts have been downgrading forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has decreased by -1.25% in the last 3 months, indicating weak earnings momentum
What is Earnings upgrade (3M)?
Not enough data
Low dividend yield
The company has a low dividend yield of 0.0%
What is Dividend yield?
Neutral
Company's earnings are of moderate quality
Earnings quality score of 35.8 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
35.8 / 100
No red flags found!
No significant red flags found in the stock.
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Holdings and Presence
Indices and prominent investors with a stake in this stock.